RxDoctor Payments DataLook up a doctor →

Alan Schulman, MD

Neurology · Richmond, VANPI 1992733034

Payments from drug & device makers

$426,037in general payments, 2019–2025

Across 990 payments — averaging $430.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$142K
  • Alkermes, Inc.$80K
  • Biogen$73K
  • EMD Serono, Inc.$42K
  • AbbVie$38K
  • Genentech, Inc.$22K
  • plus $29K from 54 others
$345in research payments, 2019–2025

Across 3 payments — averaging $115.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • EMD Serono, Inc.$345

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi67$141,803
Alkermes, Inc.34$79,818
Biogen71$73,150
EMD Serono, Inc.108$42,048
AbbVie(2 entities)164$37,940
Genentech, Inc.3$21,828
Teva Pharmaceuticals USA, Inc.34$14,726
Genentech USA, Inc.24$2,037
Novartis37$1,911
AstraZeneca(2 entities)31$1,090
UCB, Inc.47$1,005
Harmony Biosciences LLC17$515
Lundbeck LLC22$428
Lilly USA, LLC19$395
SK Life Science, Inc.14$344
Inspire Medical Systems, Inc.2$324
Eisai Inc.11$318
Kyowa Kirin, Inc.14$289
Medtronic3$258
Pfizer13$239
MDD US Operations, LLC12$229
Mallinckrodt Hospital Products Inc.8$224
Merz Pharmaceuticals, LLC7$208
Greenwich Biosciences, Inc.7$206
Amgen(2 entities)11$201
Grifols USA, LLC9$192
Alnylam Pharmaceuticals Inc.10$192
Sunovion Pharmaceuticals Inc.10$189
Acadia Pharmaceuticals Inc9$184
Neurocrine Biosciences, Inc.10$182
Johnson & Johnson(2 entities)7$179
Acorda Therapeutics, Inc7$174
Biohaven Pharmaceuticals, Inc.7$173
Neurelis, Inc.12$172
Amneal Pharmaceuticals LLC10$167
Abbott3$164
Jazz Pharmaceuticals Inc.8$163
Bristol Myers Squibb9$159
Banner Life Sciences, LLC6$158
Argenx US, Inc.5$131
CSL Behring7$130
ANI Pharmaceuticals, Inc.5$129
E.r. Squibb & Sons, L.L.C.1$125
TG Therapeutics, Inc.5$123
Avadel CNS Pharmaceuticals, LLC4$95
Avanir Pharmaceuticals, Inc.5$92
Otsuka America Pharmaceutical, Inc.4$91
Axsome Therapeutics, Inc.3$69
Biohaven Pharmaceutical Holding Company Ltd.3$64
Supernus Pharmaceuticals, Inc.3$63
Livanova USA, Inc.2$62
Catalyst Pharmaceuticals, Inc.3$56
Adamas Pharmaceuticals, Inc.3$55
Boston Scientific4$54
Mallinckrodt Enterprises LLC3$53
Life Molecular Imaging Ltd1$48
Ipsen Biopharmaceuticals, Inc2$45
Upsher-smith Laboratories LLC2$40
Revance Therapeutics, Inc.1$39
Ultragenyx Pharmaceutical Inc.2$38

How this compares

$426,037 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia →

Medicare billing

Part B allowed, 2024
$166,605
Medicare patients
786
Services billed
8,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Richmond

See the full list for Virginia →

Where these figures come from

Is this you, or does something look wrong? →